Form 4: Apogee Therapeutics CEO Michael Henderson Sells Shares Under 10b5-1 Trading Plan
SEC Filing
Apogee Therapeutics CEO Michael Henderson sold a portion of his common stock holdings on March 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Michael Henderson, CEO of Apogee Therapeutics, sold shares of common stock on March 5, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on September 25, 2023.
- A total of 7,326 shares were sold at a weighted average price of $29.98, with prices ranging from $29.49 to $30.48.
- An additional 2,674 shares were sold at a weighted average price of $30.62, with prices ranging from $30.52 to $30.96.
- Following these transactions, Henderson beneficially owns 1,292,987 shares of Apogee Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is neutral as it simply reports stock sales under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Sales by insiders are common and often pre-planned using 10b5-1 trading plans to avoid accusations of trading on inside information. The market typically views these sales in the context of the overall holdings of the insider and the reasons for the sale.
Stakeholder Impact
- The sale of shares by the CEO could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 09/25/2023 | Date of adoption of the Rule 10b5-1 trading plan. |
| 03/05/2025 | Date of the stock sale transactions. |
| 03/07/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.